Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inaticabtagene autoleucel
- Development stage
- Phase 2
- Lead developer
- Juventas Cell Therapy
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Inaticabtagene autoleucel is an autologous CD19-specific chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). It features a unique single-chain variable fragment (scFv) derived from the HI19α clone, which binds to a distinct high-affinity epitope on CD19 compared to other CAR-T therapies. The construct includes a CD8 hinge and transmembrane domain, 4-1BB costimulatory domain, and CD3 zeta signaling domain. In clinical trials, it demonstrated high overall remission rates and durable responses with manageable safety profiles. It was the first CAR T-cell therapy approved for adult r/r B-ALL in China[1][2][3][4][5][6][9].
- Brand names
- CNCT19CNCT-19CNCT 19
- Other names
- inaticabtagene autoleucel
02
Targets
Beyond the preview
Go deeper on inaticabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inaticabtagene autoleucel.